Skip to main content

AMR Action Fund opens European office in Basel

| News

AMR Action Fund opens European office in Basel


The AMR Action Fund has moved into its new European office in Basel. The venture fund is the largest public-private partnership for the development of novel antibiotics. As a result, the Basel Area now boasts a reputable newcomer to bolster its reputation as a European center in the fight against antibiotic resistance.

Messeturm Basel
AMR Action Fund is based at the Messeturm Basel (img: FlexOffice)

The AMR Action Fund has opened its European office at FlexOffice at the Messeturm Basel. According to information from the company itself, the fund, which is headquartered in Boston in the USA, is the world’s largest public-private partnership (PPP) investing in the development of novel antibiotics. Alongside numerous reputable pharma groups, the Basel-based heavyweights Roche and Novartis are among the fund’s investors. The investment and innovation promotion agency Basel Area Business & Innovation supported the AMR Action Fund’s move to Basel.

“Basel has long been a hub of biopharmaceutical innovation”, comments Martin Heidecker, Chief Investment Officer of the fund, in a press release. “Establishing a presence within the city will allow the fund to operate and identify promising investment opportunities on a truly global scale”, he adds.

In order to address the growing threat of antibiotic resistance and improve market conditions, the fund will invest around one billion US dollars in clinical-stage biotech companies with the overarching aim of bringing two to four antimicrobial drugs to the market. “Expanding our presence to Basel is good for the fund and good for the antibiotics research ecosystem in general”, explains CEO Henry Skinner.

Strong network to combat antimicrobial resistance

The fund will benefit from the fact that intensive research in the area of drugs combatting antimicrobial resistance is already being carried out in the Basel Area. For example, the INCATE and NCCR AntiResist initiatives are already established in the city, in addition to the Spearhead project. The Swiss National Center of Competence in Research (NCCR) AntiResist is financed by the Swiss National Science Foundation and sponsored by the University of Basel. For its part, the innovation incubator INCATE (Incubator for Antibacterial Therapies in Europe) is a partnership between NCCR AntiResist, the University of Basel’s innovation office and two German consortiums with four industrial partners. Spearhead, a consortium that consists of eight public and four private Swiss institutions, is likewise focused on finding solutions to the silent pandemic of antimicrobial resistance.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More